Valuation : Profound Medical Corp.

Market Cap 347M 250M 215M 202M 184M 23.87B 348M 2.39B 934M 12.05B 938M 917M 39.96B P/E 2026 *
-7.92x
P/E 2027 * -11.6x
Enterprise Value 347M 250M 215M 202M 184M 23.87B 348M 2.39B 934M 12.05B 938M 917M 39.96B EV / Sales 2026 *
9.58x
EV / Sales 2027 * 5.84x
Free-Float
95.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.45%
1 week+1.93%
Current month-8.48%
1 month-7.50%
3 months-0.73%
6 months-8.03%
Current year-11.79%
1 week 9.31
Extreme 9.31
10.21
1 month 9.03
Extreme 9.03
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.61
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
Director of Finance/CFO - 2026-08-13
President 44 2024-11-06
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Buy

Executive/Senior Manager

3,755 0.0103%
8/14/26 Other

Chief Financial Officer

0 0%
8/14/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%+1.93%+53.23%-12.04% 254M
-1.35%-1.13%+27.04%+14.12% 233B
+0.18%-1.27%+5.25%-17.37% 152B
+1.51%-1.64%-21.37%+23.59% 130B
+0.36%-7.01%-55.71%-12.92% 67.64B
+0.29%+0.47%+11.06%+18.65% 51.85B
+0.66%-1.69%-16.57%-13.62% 50.91B
-2.44%-3.25%+23.11%+28.29% 44.46B
-1.56%+0.97%+39.32%+47.34% 41.39B
-5.31%-1.74%+117.39%+36.28% 34.38B
Average -0.93%-0.66%+18.28%+11.23% 80.54B
Weighted average by Cap. -0.48%-1.49%+8.69%+9.41%

Financials

2026 *2027 *
Net sales 36.22M 26.07M 22.46M 21.06M 19.22M 2.49B 36.33M 250M 97.48M 1.26B 97.86M 95.73M 4.17B 59.46M 42.79M 36.87M 34.57M 31.56M 4.09B 59.65M 410M 160M 2.06B 161M 157M 6.85B
Net income -44.08M -31.72M -27.34M -25.63M -23.4M -3.03B -44.22M -304M -119M -1.53B -119M -117M -5.08B -31.27M -22.5M -19.39M -18.18M -16.6M -2.15B -31.36M -216M -84.16M -1.09B -84.49M -82.65M -3.6B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26-08-28 $9.500 -1.45% 9,815
26-08-27 $9.640 -2.63% 3,919
26-08-26 $9.900 +5.10% 54,179
26-08-25 $9.420 -0.63% 14,115
26-08-24 $9.480 +1.72% 5,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.500
Average target price
-

Quarterly revenue - Rate of surprise